RT @NeurologyToday@twitter.com: @US_FDA@twitter.com approves @LillyPad@twitter.com #Emgality #galcanezumab, the third #CGRP antagonist to reach the market, for #migraine treatment in adult patients. More here: https://bit.ly/2Qo0T40